Metropolis Healthcare delivered a robust financial performance in Q1 FY27, reporting a 16% year-over-year revenue growth. The growth was underpinned by a rise in patient volumes and improved revenue realizations across its service offerings, signaling healthy demand for diagnostic services during the quarter.

Key Growth Drivers

The company's revenue expansion was supported by multiple factors working in tandem. Higher patient footfall contributed meaningfully to the top-line improvement, while better revenue realizations per patient further amplified the overall growth. These twin drivers reflect both an increase in the breadth of services consumed and an enhancement in the value of services rendered.

Segment Performance

The Truhealth Wellness and Specialty segments emerged as standout performers during Q1 FY27. Strong performance in these segments indicates growing consumer adoption of wellness-focused diagnostics as well as specialized testing services, both of which are higher-value offerings within Metropolis Healthcare's portfolio. B2C registered healthy volume growth, driven by increased throughput from the expanded center network, while B2B volumes grew supported by higher wallet share and new customer acquisition.

Margin Improvement

Alongside revenue growth, Metropolis Healthcare also reported improved EBITDA margins in Q1 FY27. The margin expansion suggests that the company managed its cost base effectively even as it scaled revenues, pointing to operational leverage playing a positive role during the quarter. On a quarter-on-quarter basis, margins remained largely stable.

Metropolis Healthcare Limited promoter Ameera Sushil Shah confirmed that neither she nor other promoters and members of the promoter group created any new encumbrance on equity shares during the financial year ended March 31, 2026. The declaration, submitted to the stock exchanges, ensures compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. This disclosure is critical for shareholders as it indicates the stability of the promoter holding structure and the absence of new leverage against these shares for the period.

The filing detailed the shareholding and encumbrance status of all promoters and promoter group members as of March 31, 2026. While the majority of entities reported zero encumbrances, Metz Advisory LLP, a promoter, disclosed that 12,00,000 of its 6,27,64,864 equity shares remain encumbered. This specific encumbrance was previously disclosed and represents the only outstanding charge against the promoter group's holdings.

The declaration was made on behalf of all promoters and members of the promoter group, including entities such as Duru Shah Family Trust and Sushil Shah Family Trust. Ameera Sushil Shah holds 7,27,380 shares, while the Sushil Shah Family Trust holds 1,49,00,980 shares, both with zero encumbrances. The confirmation was digitally signed and submitted to the Audit Committee, BSE Limited, and National Stock Exchange of India Ltd.

Shareholding and Encumbrance Details

The following table outlines the shareholding and encumbrance status of key promoters as of March 31, 2026:

The document explicitly states that apart from the disclosed encumbrance held by Metz Advisory LLP, no other shares held by the promoters or the promoter group are encumbered directly or indirectly. The confirmation provides transparency regarding the financial pledges associated with the company's top ownership.